[go: up one dir, main page]

MX2019002166A - Agonistas del receptor cxcr3. - Google Patents

Agonistas del receptor cxcr3.

Info

Publication number
MX2019002166A
MX2019002166A MX2019002166A MX2019002166A MX2019002166A MX 2019002166 A MX2019002166 A MX 2019002166A MX 2019002166 A MX2019002166 A MX 2019002166A MX 2019002166 A MX2019002166 A MX 2019002166A MX 2019002166 A MX2019002166 A MX 2019002166A
Authority
MX
Mexico
Prior art keywords
agonists
cxcr3 receptor
compounds
cxcr3
receptor
Prior art date
Application number
MX2019002166A
Other languages
English (en)
Other versions
MX380217B (es
Inventor
Tamiya Junko
Zhang Lin
YEAGER Adam
Turnbull Philip
Fan Junhua
Steinberg Marcos
FOWLER Tom
Benelkebir Hanae
Pasceri Raffaele
Ieva Maria
GRANT Kevan
TRAN Yang
Original Assignee
Celgene Int Ii Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Int Ii Sarl filed Critical Celgene Int Ii Sarl
Publication of MX2019002166A publication Critical patent/MX2019002166A/es
Publication of MX380217B publication Critical patent/MX380217B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan compuestos que tienen la estructura de la siguiente fórmula I: (ver Fórmula) donde R, R1, R2, R3a y R3b son como se definen en la presente. También se proporcionan composiciones farmacéuticas que comprenden estos compuestos, así como métodos relacionados a su elaboración y uso.
MX2019002166A 2016-09-02 2017-08-31 Agonistas del receptor cxcr3. MX380217B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383202P 2016-09-02 2016-09-02
US201762478496P 2017-03-29 2017-03-29
PCT/US2017/049768 WO2018045246A1 (en) 2016-09-02 2017-08-31 Cxcr3 receptor agonists

Publications (2)

Publication Number Publication Date
MX2019002166A true MX2019002166A (es) 2019-06-12
MX380217B MX380217B (es) 2025-03-12

Family

ID=59846729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002166A MX380217B (es) 2016-09-02 2017-08-31 Agonistas del receptor cxcr3.

Country Status (8)

Country Link
US (2) US20190345133A1 (es)
EP (1) EP3507275B1 (es)
JP (1) JP7181857B2 (es)
AU (1) AU2017318674B2 (es)
CA (1) CA3034108A1 (es)
ES (1) ES2950560T3 (es)
MX (1) MX380217B (es)
WO (1) WO2018045246A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230181691A1 (en) 2020-02-12 2023-06-15 The Regents Of The University Of California Platelet factors and cognitive improvement
CN111943823A (zh) * 2020-09-16 2020-11-17 安徽工业大学 一种苯菌酮的制备方法
CN116178383B (zh) * 2022-12-26 2025-04-22 南方科技大学 生物碱及三价铁卟啉催化合成生物碱的方法

Also Published As

Publication number Publication date
US11040954B1 (en) 2021-06-22
AU2017318674A1 (en) 2019-03-28
MX380217B (es) 2025-03-12
ES2950560T3 (es) 2023-10-11
WO2018045246A1 (en) 2018-03-08
AU2017318674B2 (en) 2020-11-12
CA3034108A1 (en) 2018-03-08
EP3507275A1 (en) 2019-07-10
JP2019533639A (ja) 2019-11-21
JP7181857B2 (ja) 2022-12-01
US20190345133A1 (en) 2019-11-14
EP3507275B1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
DOP2016000145A (es) Reguladores de nrf2
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
UY35500A (es) Indazoles sustituidos con heteroarilo
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
UY36311A (es) Indazoles sustituidos con bencilo
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CR20130671A (es) Antagonistas de trpv4
CO2019006673A2 (es) Polimorfos
CO2019006687A2 (es) Polimorfos
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
MX2019002166A (es) Agonistas del receptor cxcr3.